Alterity Therapeutics Limited (NASDAQ: ATHE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $8.00 price target on the stock.
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium [Yahoo! Finance]
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium